Vascular COX-2 modulates blood pressure and thrombosis in mice

Science Translational Medicine

Volumn 4, Issue 132, 2012, Pages

  Yu, Ying ^a,e   Ricciotti, Emanuela ^a   Scalia, Rosario ^b   Tang, Soon Yew ^a   Grant, Gregory ^a   Yu, Zhou ^a   Landesberg, Gavin ^b   Crichton, Irene ^c   Wu, Weichen ^a   Puré, Ellen ^c   Funk, Colin D ^d   FitzGerald, Garret A ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b TEMPLE UNIVERSITY   (United States)

^c WISTAR INSTITUTE   (United States)

^d QUEEN S UNIVERSITY   (Canada)

^e Shanghai Jiao Tong University Affiliated Sixth People s Hospital   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2; ENDOTHELIAL NITRIC OXIDE SYNTHASE; NITRIC OXIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTACYCLIN; PTGS2 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE REGULATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME MECHANISM; ENZYME REGULATION; ENZYME RELEASE; ENZYME REPRESSION; ENZYME SYNTHESIS; HYPERTENSION; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; THROMBOSIS; TISSUE SPECIFICITY; URINARY EXCRETION; VASCULAR SMOOTH MUSCLE; VASCULARIZATION; ANIMAL; ANTIBODY SPECIFICITY; BIOSYNTHESIS; BLOOD PRESSURE; BLOOD VESSEL; C57BL MOUSE; ENZYMOLOGY; GENE DELETION; HOMEOSTASIS; METABOLISM; MOUSE MUTANT; PATHOPHYSIOLOGY; PHYSIOLOGY; SYSTOLE;

ANIMALS; BLOOD PRESSURE; BLOOD VESSELS; CYCLOOXYGENASE 2; EPOPROSTENOL; GENE DELETION; HOMEOSTASIS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NITRIC OXIDE; ORGAN SPECIFICITY; SYSTOLE; THROMBOSIS;

EID: 84860703445     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3003787     Document Type: Article

References (29)

1. B. F. McAdam, F. Catella-Lawson, I. A. Mardini, S. Kapoor, J. A. Lawson, G. A. FitzGerald, Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: The human pharmacology of a selective inhibitor of COX-2. Proc. Natl. Acad. Sci. U.S.A. 96, 272-277 (1999).
2. F. Catella-Lawson, B. McAdam, B. W. Morrison, S. Kapoor, D. Kujubu, L. Antes, K. C. Lasseter, H. Quan, B. J. Gertz, G. A. FitzGerald, Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. J. Pharmacol. Exp. Ther. 289, 735-741 (1999).
3. S. Moncada, J. R. Vane, Prostacyclin and the vascular endothelium. Bull. Eur. Physiopathol. Respir. 17, 687-701 (1981).
4. J. N. Topper, J. Cai, D. Falb, M. A. Gimbrone Jr., Identification of vascular endothelial genes differentially responsive to fluid mechanical stimuli: Cyclooxygenase-2, manganese superoxide dismutase, and endothelial cell nitric oxide synthase are selectively up-regulated by steady laminar shear stress. Proc. Natl. Acad. Sci. U.S.A. 93, 10417-10422 (1996).
5. N. A. Flavahan, Balancing prostanoid activity in the human vascular system. Trends Pharmacol. Sci. 28, 106-110 (2007).
6. J. A. Mitchell, R. Lucas, I. Vojnovic, K. Hasan, J. R. Pepper, T. D. Warner, Stronger inhibition by nonsteroid anti-inflammatory drugs of cyclooxygenase-1 in endothelial cells than platelets offers an explanation for increased risk of thrombotic events. FASEB J. 20, 2468-2475 (2006).
7. T. Grosser, Y. Yu, G. A. FitzGerald, Emotion recollected in tranquility: Lessons learned from the COX-2 saga. Annu. Rev. Med. 61, 17-33 (2010).
8. Y. Cheng, S. C. Austin, B. Rocca, B. H. Koller, T. M. Coffman, T. Grosser, J. A. Lawson, G. A. FitzGerald, Role of prostacyclin in the cardiovascular response to thromboxane A2. Science 296, 539-541 (2002).
9. W. J. Elliott, Do the blood pressure effects of nonsteroidal antiinflammatory drugs influence cardiovascular morbidity and mortality? Curr. Hypertens. Rep. 12, 258-266 (2010).
10. P. McGettigan, D. Henry, Cardiovascular risk with non-steroidal anti-inflammatory drugs: Systematic review of population-based controlled observational studies. PLoS Med. 8, e1001098 (2011).
11. F. Krötz, L. Struthmann, A review on the risk of myocardial infarction associated with the NSAID diclofenac. Cardiovasc. Hematol. Disord. Drug Targets 10, 53-65 (2010).
12. T. D. Warner, J. A. Mitchell, COX-2 selectivity alone does not define the cardiovascular risks associated with non-steroidal anti-inflammatory drugs. Lancet 371, 270-273 (2008).
13. Y. Cheng, M. Wang, Y. Yu, J. Lawson, C. D. Funk, G. A. FitzGerald, Cyclooxygenases, microsomal prostaglandin E synthase-1, and cardiovascular function. J. Clin. Invest. 116, 1391-1399 (2006).
14. Z. Yu, I. Crichton, S. Y. Tang, Y. Hui, E. Ricciotti,M.D. Levin, J. A. Lawson, E. Pure, G. A. FitzGerald, Disruption of the 5-lipoxygenase pathway attenuates atherogenesis consequent to COX-2 deletion in mice. Proc. Natl. Acad. Sci. U.S.A. 10.1073/pnas.1115313109 (2012).
15. Y. Yu, J. Stubbe, S. Ibrahim, W. L. Song, E. M. Smyth, C. D. Funk, G. A. FitzGerald, Cyclooxygenase-2-dependent prostacyclin formation and blood pressure homeostasis: Targeted exchange of cyclooxygenase isoforms in mice. Circ. Res. 106, 337-345 (2010).
16. I. A. Reilly, G. A. FitzGerald, Inhibition of thromboxane formation in vivo and ex vivo: Implications for therapy with platelet inhibitory drugs. Blood 69, 180-186 (1987).
17. T. Hla, K. Neilson, Human cyclooxygenase-2 cDNA. Proc. Natl. Acad. Sci. U.S.A. 89, 7384-7388 (1992).
18. T. Grosser, S. Fries, G. A. FitzGerald, Biological basis for the cardiovascular consequences of COX-2 inhibition: Therapeutic challenges and opportunities. J. Clin. Invest. 116, 4-15 (2006).
19. S. Moncada, E. A. Higgs, J. R. Vane, Human arterial and venous tissues generate prostacyclin (prostaglandin X), a potent inhibitor of platelet aggregation. Lancet 1, 18-20 (1977).
20. Z. Qi, C. M. Hao, R. I. Langenbach, R. M. Breyer, R. Redha, J. D. Morrow, M. D. Breyer, Opposite effects of cyclooxygenase-1 and -2 activity on the pressor response to angiotensin II. J. Clin. Invest. 110, 61-69 (2002).
21. 2 receptor. Nat. Med. 5, 217-220 (1999).
22. P. M. Kearney, C. Baigent, J. Godwin, H. Halls, J. R. Emberson, C. Patrono, Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ 332, 1302-1308 (2006).
23. G. A. FitzGerald, COX-2 in play at the AHA and the FDA. Trends Pharmacol. Sci. 28, 303-307 (2007).
24. D. Wang, V. V. Patel, E. Ricciotti, R. Zhou, M. D. Levin, E. Gao, Z. Yu, V. A. Ferrari, M. M. Lu, J. Xu, H. Zhang, Y. Hui, Y. Cheng, N. Petrenko, Y. Yu, G. A. FitzGerald, Cardiomyocyte cyclooxygenase-2 influences cardiac rhythm and function. Proc. Natl. Acad. Sci. U.S.A. 106, 7548-7552 (2009).
25. J. J. Lepore, L. Cheng, M. Min Lu, P. A. Mericko, E. E. Morrisey, M. S. Parmacek, High-efficiency somatic mutagenesis in smooth muscle cells and cardiac myocytes in SM22α-Cre transgenic mice. Genesis 41, 179-184 (2005).
26. Y. Y. Kisanuki, R. E. Hammer, J. Miyazaki, S. C. Williams, J. A. Richardson, M. Yanagisawa, Tie2-Cre transgenic mice: A new model for endothelial cell-lineage analysis in vivo. Dev. Biol. 230, 230-242 (2001).
27. J. M. Miano, N. Ramanan, M. A. Georger, K. L. de Mesy Bentley, R. L. Emerson, R. O. Balza Jr., Q. Xiao, H. Weiler, D. D. Ginty, R. P. Misra, Restricted inactivation of serum response factor to the cardiovascular system. Proc. Natl. Acad. Sci. U.S.A. 101, 17132-17137 (2004).
28. N. Takakura, X. L. Huang, T. Naruse, I. Hamaguchi, D. J. Dumont, G. D. Yancopoulos, T. Suda, Critical role of the TIE2 endothelial cell receptor in the development of definitive hematopoiesis. Immunity 9, 677-686 (1998).
29. S. T. Pleger, D. M. Harris, C. Shan, L. E. Vinge, J. K. Chuprun, B. Berzins,W. Pleger, C. Druckman, M. Volkers, J. Heierhorst, E. Øie, A. Remppis, H. A. Katus, R. Scalia, A. D. Eckhart, W. J. Koch, P. Most, Endothelial S100A1 modulates vascular function via nitric oxide. Circ. Res. 102, 786-794 (2008).